Pertussis prevention

Reasons for resurgence, and differences in the current acellular pertussis vaccines

World Association of Infectious Diseases and Immunological Disorders (WAidid), Vaccine Study Group of the European Society of Clinical Microbiology and Infectious Diseases (EVASG)

Research output: Contribution to journalArticle

Abstract

Pertussis is an acute respiratory disease caused by Bordetella pertussis. Due to its frequency and severity, prevention of pertussis has been considered an important public health issue for many years. The development of the whole-cell pertussis vaccine (wPV) and its introduction into the pediatric immunization schedule was associated with a marked reduction in pertussis cases in the vaccinated cohort. However, due to the frequency of local and systemic adverse events after immunization with wPV, work on a less reactive vaccine was undertaken based on isolated B. pertussis components that induced protective immune responses with fewer local and systemic reactions. These component vaccines were termed acellular vaccines and contained one or more pertussis antigens, including pertussis toxin (PT), filamentous haemagglutinin (FHA), pertactin (PRN), and fimbrial proteins 2 (FIM2) and 3 (FIM3). Preparations containing up to five components were developed, and several efficacy trials clearly demonstrated that the aPVs were able to confer comparable short-term protection than the most effective wPVs with fewer local and systemic reactions. There has been a resurgence of pertussis observed in recent years. This paper reports the results of a Consensus Conference organized by the World Association for Infectious Disease and Immunological Disorders (WAidid) on June 22, 2018, in Perugia, Italy, with the goal of evaluating the most important reasons for the pertussis resurgence and the role of different aPVs in this resurgence.

Original languageEnglish (US)
Article number1344
JournalFrontiers in immunology
Volume10
Issue numberJUL
DOIs
StatePublished - Jan 1 2019

Fingerprint

Acellular Vaccines
Pertussis Vaccine
Whooping Cough
Bordetella pertussis
Vaccines
Immunization Schedule
Pertussis Toxin
Hemagglutinins
Acute Disease
Italy
Communicable Diseases
Immunization
Public Health
Pediatrics
Antigens

Keywords

  • Acellular pertussis vaccine
  • Bordetella pertussis
  • Pertussis
  • Whole-cell pertussis vaccin pertussis prevention

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

World Association of Infectious Diseases and Immunological Disorders (WAidid), & Vaccine Study Group of the European Society of Clinical Microbiology and Infectious Diseases (EVASG) (2019). Pertussis prevention: Reasons for resurgence, and differences in the current acellular pertussis vaccines. Frontiers in immunology, 10(JUL), [1344]. https://doi.org/10.3389/fimmu.2019.01344
World Association of Infectious Diseases and Immunological Disorders (WAidid) ; Vaccine Study Group of the European Society of Clinical Microbiology and Infectious Diseases (EVASG). / Pertussis prevention : Reasons for resurgence, and differences in the current acellular pertussis vaccines. In: Frontiers in immunology. 2019 ; Vol. 10, No. JUL.
@article{0cf0338a180a4702852ee972b4424de2,
title = "Pertussis prevention: Reasons for resurgence, and differences in the current acellular pertussis vaccines",
abstract = "Pertussis is an acute respiratory disease caused by Bordetella pertussis. Due to its frequency and severity, prevention of pertussis has been considered an important public health issue for many years. The development of the whole-cell pertussis vaccine (wPV) and its introduction into the pediatric immunization schedule was associated with a marked reduction in pertussis cases in the vaccinated cohort. However, due to the frequency of local and systemic adverse events after immunization with wPV, work on a less reactive vaccine was undertaken based on isolated B. pertussis components that induced protective immune responses with fewer local and systemic reactions. These component vaccines were termed acellular vaccines and contained one or more pertussis antigens, including pertussis toxin (PT), filamentous haemagglutinin (FHA), pertactin (PRN), and fimbrial proteins 2 (FIM2) and 3 (FIM3). Preparations containing up to five components were developed, and several efficacy trials clearly demonstrated that the aPVs were able to confer comparable short-term protection than the most effective wPVs with fewer local and systemic reactions. There has been a resurgence of pertussis observed in recent years. This paper reports the results of a Consensus Conference organized by the World Association for Infectious Disease and Immunological Disorders (WAidid) on June 22, 2018, in Perugia, Italy, with the goal of evaluating the most important reasons for the pertussis resurgence and the role of different aPVs in this resurgence.",
keywords = "Acellular pertussis vaccine, Bordetella pertussis, Pertussis, Whole-cell pertussis vaccin pertussis prevention",
author = "{World Association of Infectious Diseases and Immunological Disorders (WAidid)} and {Vaccine Study Group of the European Society of Clinical Microbiology and Infectious Diseases (EVASG)} and Susanna Esposito and Paola Stefanelli and Fry, {Norman K.} and Giorgio Fedele and Qiushui He and Pauline Paterson and Tan, {Tina Quanbee} and Markus Knuf and Carlos Rodrigo and Olivier, {Catherine Weil} and Flanagan, {Katie L.} and Ivan Hung and Iria Lutsar and Kathryn Edwards and Miguel O'Ryan and Nicola Principi",
year = "2019",
month = "1",
day = "1",
doi = "10.3389/fimmu.2019.01344",
language = "English (US)",
volume = "10",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",
number = "JUL",

}

World Association of Infectious Diseases and Immunological Disorders (WAidid) & Vaccine Study Group of the European Society of Clinical Microbiology and Infectious Diseases (EVASG) 2019, 'Pertussis prevention: Reasons for resurgence, and differences in the current acellular pertussis vaccines', Frontiers in immunology, vol. 10, no. JUL, 1344. https://doi.org/10.3389/fimmu.2019.01344

Pertussis prevention : Reasons for resurgence, and differences in the current acellular pertussis vaccines. / World Association of Infectious Diseases and Immunological Disorders (WAidid); Vaccine Study Group of the European Society of Clinical Microbiology and Infectious Diseases (EVASG).

In: Frontiers in immunology, Vol. 10, No. JUL, 1344, 01.01.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pertussis prevention

T2 - Reasons for resurgence, and differences in the current acellular pertussis vaccines

AU - World Association of Infectious Diseases and Immunological Disorders (WAidid)

AU - Vaccine Study Group of the European Society of Clinical Microbiology and Infectious Diseases (EVASG)

AU - Esposito, Susanna

AU - Stefanelli, Paola

AU - Fry, Norman K.

AU - Fedele, Giorgio

AU - He, Qiushui

AU - Paterson, Pauline

AU - Tan, Tina Quanbee

AU - Knuf, Markus

AU - Rodrigo, Carlos

AU - Olivier, Catherine Weil

AU - Flanagan, Katie L.

AU - Hung, Ivan

AU - Lutsar, Iria

AU - Edwards, Kathryn

AU - O'Ryan, Miguel

AU - Principi, Nicola

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Pertussis is an acute respiratory disease caused by Bordetella pertussis. Due to its frequency and severity, prevention of pertussis has been considered an important public health issue for many years. The development of the whole-cell pertussis vaccine (wPV) and its introduction into the pediatric immunization schedule was associated with a marked reduction in pertussis cases in the vaccinated cohort. However, due to the frequency of local and systemic adverse events after immunization with wPV, work on a less reactive vaccine was undertaken based on isolated B. pertussis components that induced protective immune responses with fewer local and systemic reactions. These component vaccines were termed acellular vaccines and contained one or more pertussis antigens, including pertussis toxin (PT), filamentous haemagglutinin (FHA), pertactin (PRN), and fimbrial proteins 2 (FIM2) and 3 (FIM3). Preparations containing up to five components were developed, and several efficacy trials clearly demonstrated that the aPVs were able to confer comparable short-term protection than the most effective wPVs with fewer local and systemic reactions. There has been a resurgence of pertussis observed in recent years. This paper reports the results of a Consensus Conference organized by the World Association for Infectious Disease and Immunological Disorders (WAidid) on June 22, 2018, in Perugia, Italy, with the goal of evaluating the most important reasons for the pertussis resurgence and the role of different aPVs in this resurgence.

AB - Pertussis is an acute respiratory disease caused by Bordetella pertussis. Due to its frequency and severity, prevention of pertussis has been considered an important public health issue for many years. The development of the whole-cell pertussis vaccine (wPV) and its introduction into the pediatric immunization schedule was associated with a marked reduction in pertussis cases in the vaccinated cohort. However, due to the frequency of local and systemic adverse events after immunization with wPV, work on a less reactive vaccine was undertaken based on isolated B. pertussis components that induced protective immune responses with fewer local and systemic reactions. These component vaccines were termed acellular vaccines and contained one or more pertussis antigens, including pertussis toxin (PT), filamentous haemagglutinin (FHA), pertactin (PRN), and fimbrial proteins 2 (FIM2) and 3 (FIM3). Preparations containing up to five components were developed, and several efficacy trials clearly demonstrated that the aPVs were able to confer comparable short-term protection than the most effective wPVs with fewer local and systemic reactions. There has been a resurgence of pertussis observed in recent years. This paper reports the results of a Consensus Conference organized by the World Association for Infectious Disease and Immunological Disorders (WAidid) on June 22, 2018, in Perugia, Italy, with the goal of evaluating the most important reasons for the pertussis resurgence and the role of different aPVs in this resurgence.

KW - Acellular pertussis vaccine

KW - Bordetella pertussis

KW - Pertussis

KW - Whole-cell pertussis vaccin pertussis prevention

UR - http://www.scopus.com/inward/record.url?scp=85069052016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069052016&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2019.01344

DO - 10.3389/fimmu.2019.01344

M3 - Article

VL - 10

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - JUL

M1 - 1344

ER -

World Association of Infectious Diseases and Immunological Disorders (WAidid), Vaccine Study Group of the European Society of Clinical Microbiology and Infectious Diseases (EVASG). Pertussis prevention: Reasons for resurgence, and differences in the current acellular pertussis vaccines. Frontiers in immunology. 2019 Jan 1;10(JUL). 1344. https://doi.org/10.3389/fimmu.2019.01344